Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma

AIDS

Volumn 10, Issue 5, 1996, Pages 515-519

  Uthayakumar, Sundaralingam ^a   Bower, Mark ^a,b   Money Kyrle, Julian ^a   Muyshondt, Carine ^c   Youle, Mike ^a   Hannon, Frances ^a   Phillips, Robert ^a   Gazzard, Brian G ^a   Boag, Fiona ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c Vestar Inc   (Belgium)

Author keywords

Cancers; Chemotherapy; Kaposi's sarcoma; Therapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; LIPOSOME;

ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EDEMA; FATIGUE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URTICARIA; VOMITING;

EID: 0029983462     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199605000-00010     Document Type: Article

References (26)

1. Fife K, Bower M: Recent advances in the pathogenesis of AIDS-related Kaposi's sarcoma. Br J Cancer 1996 (in press).
2. Volm M, Von Roenn J: Treatment strategies for epidemic Kaposi's sarcoma. Curr Opinion Oncology 1995, 7:429-436.
3. Real FX, Krown SE, Oettgen HF: Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986, 4:544-551.
4. Forssen EA, Tokes ZA: Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA 1981, 78:1873-1877.
5. Rahman A, More N, Schein PS: Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 1982, 42:1817-1825.
6. Rahman A, White G, More N, Schein PS: Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1985, 45:796-803.
7. Harrison M, Tomlinson D, Stewart S: Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sracoma. J Clin Oncol 1995, 13:914-920.
8. Bogner JR, Kronawitter U, Rolinski B, Truebenbach K, Goebel FD: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994, 7:463-468.
9. Simpson JK, Miller RF, Spittle MF: Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin Oncol R Col Radiol 1993, 5:372-374.
10. Sturzl M, Zietz C, Eisenburg B, et al.: Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: clinical, histological and cell biological evaluation. Res Virol 1994, 145:261-269.
11. Money Kyrle J, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC: Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol R Col Radiol 1993, 5:367-371.
12. Presant CA, Scolaro M, Kennedy P, et al.: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993, 341:1242-1243.
13. Eckardt JR, Campbell E, Burris HA, et al.: A phase II trial of liposomal daunorubicin, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol 1994, 17:498-501.
14. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989, 7:1201-1207.
15. World Health Organisation. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO; 1979 (offset publication no. 48).
16. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961, 13:346-353.
17. Laubenstein LJ, Krigel RL, Odajnyk CM, et al.: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984, 2: 1115-1120.
18. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J: Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 103:335-338.
19. Remick SC, Reddy M, Herman D, et al.: Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma. J Clin Oncol 1994, 12:1130-1136.
20. Gill PS, Rarick M, McCutchan JA, et al.: Systemic treatment of AIDS-relaled Kaposi's sarcoma: results of a randomized trial. Am J Med 1991, 90:427-433.
21. Fischl MA, Known SE, O'Boyle KP, et al.: Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1993, 6:259-264.
22. Saville MW, Lietzau J, Pluda JM, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995, 346:26-28.
23. Gill P, Rarick M, Bernstein SM, et al.: Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990, 13:315-319.
24. Kaplan L, Abrams D, Volberding P: Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 1986, 70:1121-1122.
25. ® liposomal doxorubicin (D-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 1994, 13:55.
26. Gill PS, Wernz J, Scadden DT, et al.: A randomized trial of liposomal daunorubicin (liposomal daunorubicin) versus adriamycin, bleomycin, and vincristine (ABV) in 232 patients with advanced AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 1995, 14:291.